Compare · ACON vs NTRA
ACON vs NTRA
Side-by-side comparison of Aclarion Inc. (ACON) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACON and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $30.57B, about 3695.3x ACON ($8.3M).
- NTRA has been more active in the news (16 items in the past 4 weeks vs 7 for ACON).
- NTRA has more recent analyst coverage (25 ratings vs 0 for ACON).
- Company
- Aclarion Inc.
- Natera Inc.
- Price
- -
- -
- Market cap
- $8.3M
- $30.57B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2015
- News (4w)
- 7
- 16
- Recent ratings
- 0
- 25
Aclarion Inc.
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest ACON
- Aclarion Rejects Echo Lake Capital's Unsolicited Acquisition Proposal
- Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting
- Aclarion Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
- Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study
- Aclarion, Inc. Comments on Echo Lake Capital's Letter and Unsolicited Proposal
- Echo Lake Capital Offers To Acquire Aclarion Inc.
- SEC Form 10-Q filed by Aclarion Inc.
- Director Breidbart Scott bought $18,012 worth of shares (5,664 units at $3.18) (SEC Form 4)
- Director Neal David K bought $7,750 worth of shares (2,500 units at $3.10), increasing direct ownership by 125,000% to 2,502 units (SEC Form 4)
Latest NTRA
- CEO AND PRESIDENT Chapman Steven Leonard sold $9,089,776 worth of shares (41,124 units at $221.03) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 108,743 units (SEC Form 4)
- Natera Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $655,295 worth of shares (3,000 units at $218.43) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 137,643 units (SEC Form 4)
- Director Rubin Eric H was granted 2,124 shares, increasing direct ownership by 42,480% to 2,129 units (SEC Form 4)
- Director Botha Roelof sold $17,184,092 worth of shares (78,000 units at $220.31) (SEC Form 4)
- Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
- Wolfe Research resumed coverage on Natera with a new price target
- SEC Form 144 filed by Natera Inc.
- Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma